| 59.345 0.895 (1.53%) | 09-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 77.52 | 1-year : | 90.54 |
| Resists | First : | 66.37 | Second : | 77.52 |
| Pivot price | 61.42  |
|||
| Supports | First : | 50.45 | Second : | 40.61 |
| MAs | MA(5) : | 60.01 |
MA(20) : | 58.31 |
| MA(100) : | 38.95 |
MA(250) : | 26.53 |
|
| MACD | MACD : | 3.6 |
Signal : | 4.5 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 51.3 |
| RSI | RSI(14): 58.4 |
|||
| 52-week | High : | 66.37 | Low : | 14.27 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ETON ] has closed above bottom band by 20.2%. Bollinger Bands are 39.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 60.07 - 60.4 | 60.4 - 60.71 |
| Low: | 55.76 - 56.19 | 56.19 - 56.58 |
| Close: | 58.71 - 59.35 | 59.35 - 59.93 |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Sun, 06 Sep 2026
118,249 Shares in Eton Pharmaceuticals, Inc. $ETON Purchased by Bank of New York Mellon Corp - MarketBeat
Sat, 05 Sep 2026
(ETON) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Wed, 02 Sep 2026
Sigma Planning Corp Takes Position in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Mon, 31 Aug 2026
Eton Pharmaceuticals (ETON) director unloads 50K shares after option exercise - Stock Titan
Fri, 28 Aug 2026
Bank of Nova Scotia Acquires New Position in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Fri, 28 Aug 2026
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 29 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 70.2 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | 0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | 12 % |
| Operating Margin | 35.7 % |
| Return on Assets (ttm) | 11.8 % |
| Return on Equity (ttm) | 35.9 % |
| Qtrly Rev. Growth | 98.5 % |
| Gross Profit (p.s.) | 2.26 |
| Sales Per Share | 3.69 |
| EBITDA (p.s.) | 0.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 15 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | 152.16 |
| PEG Ratio | 0 |
| Price to Book value | 35.96 |
| Price to Sales | 16.06 |
| Price to Cash Flow | 112.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|